Monoclonal antibodies as anti-infective products: a promising future?

ABSTRACT:

Background

The paucity of licensed monoclonal antibodies (mAbs) in the infectious diseases arena strongly contrasts with the ready availability of these therapeutics for use in other conditions.

Aims

This narrative review aims to assess the potential of monoclonal antibody-based interventions for infectious diseases.

Sources

A review of the literature via the Medline database was performed and complemented by published official documents on licensed anti-infective mAbs. In addition, ongoing trials were identified through a search of the clinical trial registration platform ClinicalTrials.gov.

Content

We identified the few infections for which mAbs have been added to the therapeutic armamentarium and stressed their potential in representing a readily available p

SUBMITTER: Pelfrene E 

PROVIDER: S-EPMC7128139 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature